Associations of low-level urine cadmium with kidney function in lead workers

Virginia M Weaver,1,2 Nam-Soo Kim,3 Bernard G Jaar,2,4 Brian S Schwartz,1,2,4 Patrick J Parsons,5,6 Amy J Steuerwald,5,6 Andrew C Todd,7 David Simon,8 Byung-Kook Lee3

ABSTRACT

Objectives Low-level cadmium exposure, resulting in, for example, urinary cadmium <2.0 µg/g creatinine, is widespread; recent data suggest nephrotoxicity even at these low levels. Few studies have examined the impact of low-level cadmium exposure in workers who are occupationally exposed to other nephrotoxins such as lead.

Methods We evaluated associations of urine cadmium, a measure of cumulative dose, with four glomerular filtration measures and N-acetyl-β-D-glucosaminidase (NAG) in lead workers. Recent and cumulative lead doses were assessed via blood andibia lead, respectively.

Results In 712 lead workers, mean (SD) blood andibia lead values, urinary cadmium values and estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease equation were 23.1 (14.1) µg/dl, 26.6 (28.9) µg Pb/g bone mineral, 1.15 (0.66) µg/g creatinine and 97.4 (19.2) ml/min/1.73 m², respectively. After adjustment for age, sex, body mass index, urine creatinine and smoking, alcohol, education, annual income, diastolic blood pressure, current or former lead worker job status, new or returning study participant, and blood andibia lead, higher In-urine cadmium was associated with higher calculated creatinine clearance, eGFR (β=8.7 ml/min/1.73 m², 95% CI 5.4 to 12.1) and In-NAG but lower serum creatinine.

Conclusions Potential explanations for these results include a normal physiological response in which urine cadmium levels reflect renal filtration, the impact of adjustment for urine dilution with creatinine in models of kidney outcomes, and cadmium-related hyperfiltration.

INTRODUCTION

Low-level, environmental cadmium exposure, resulting in urinary cadmium <2.0 µg/g creatinine, is widespread. Similar to lead, cadmium is a kidney proximal tubular toxicant that accumulates in the body resulting in chronic endogenous exposure. A known cause of chronic kidney disease (CKD) in the occupational setting, recent data indicate nephrotoxicity at lower levels of exposure. Furthermore, in a recent US general population analysis, participants with higher levels of both blood lead and cadmium had increased risk for an estimated glomerular filtration rate (eGFR) of <60 ml/min/1.73 m² compared to those with lower levels of both metals. Thus, environmental cadmium exposure may contribute to nephrotoxicity in lead workers. To address this hypothesis, we performed a cross-sectional analysis examining associations between urine cadmium, a measure of cumulative dose, and kidney function in 712 current and former lead workers in the Republic of Korea.

MATERIALS AND METHODS

Study overview and design

We carried out a cross-sectional analysis of data from current and former lead workers who completed the fourth evaluation in a longitudinal study of inorganic lead exposed workers. Evaluations were performed between 8 April 2004 and 24 September 2005. All participants provided written, informed consent. The study protocol was approved by Institutional Review Boards at the Soonchunhyang University School of Medicine and the Johns Hopkins University Bloomberg School of Public Health. Participation in the study was voluntary, and workers were paid approximately US$50 for their time and effort.

Study population

As previously described, participants in the initial cohort of this study were recruited between 1997 and 1999 (phase I study participants) from 26 facilities including secondary lead smelters and plants producing lead batteries, lead oxide, lead crystal or radiators. The study population is 100% Korean. The original participants were followed longitudinally for three annual evaluations. In 2004, recruitment for three additional annual evaluations was begun; 498 of the 803 (62%) lead workers in the original phase I cohort were re-enrolled. Due to the economic conditions in Asia during the late 1990s, many workers in the initial
study cohort had been laid off and lost to follow-up. In addition, 279 new participants were recruited (phase II study participants) from 18 of the original facilities and four new facilities including automobile battery, instrument and lead crystal manufacturers and a primary lead smelter. Inclusion criteria included occupational lead exposure and, for new participants, age ≥40 years in order to enrich the study with participants at greater risk for adverse kidney outcomes. No medical exclusionary criteria were used. At the end of this second enrolment phase (24 September 2005), 778 current and former lead workers had completed the fourth of six evaluations in the overall longitudinal study. In order to optimise study data for both cross-sectional and longitudinal cadmium analyses while addressing funding constraints, urine cadmium was measured in fourth evaluation samples in the 712 workers who came to both the fourth and fifth evaluations. Cross-sectional analysis of fourth evaluation data in these 712 workers is the focus of the current analysis.

Data collection
Data collection for large employers was completed at the study plants. Workers from smaller facilities and former lead workers were evaluated at the Institute of Industrial Medicine of the Soonchunhyang University in Asan, the University Hospital in Chonan or hospitals near their current or former workplaces. A standardised, interviewer-administered questionnaire was used to elicit information on demographics, medical history including physician diagnoses, medication, smoking and alcohol use, education, income and occupational history. Blood pressure was measured with the IntelliSense blood pressure monitor (Model HEM-907; Omron, Vernon Hills, Illinois, USA) with an appropriately sized cuff using a standardised protocol in which the participant was seated for 5 min before three measurements at 30 s intervals were obtained. Data and biological specimens also included height and weight measurements to assess body mass index (BMI; weight in kilograms divided by the square of height in metres), a blood specimen (for serum creatinine and blood lead as a recent dose measure), 4 h urine collection (for creatinine to calculate creatinine clearance and cadmium (cumulative exposure measure except in cadmium nephropathy)), a spot urine sample collected just before starting the 4 h urine collection (for creatinine and a primary lead smelter. Inclusion criteria included occupa-

Laboratory methods
Urine cadmium was measured in the Trace Elements section of the Laboratory of Inorganic and Nuclear Chemistry at the New York State (NYS) Department of Health’s Wadsworth Center (Albany, New York, USA) which is NYS’s principal reference laboratory for the measurement of trace metals in urine. Urine specimens for cadmium analysis were collected and frozen in containers that were pre-certified for low-level trace element measurements by the analysing laboratory and stored at ~80°C in 5 ml Nalgene cryogenic polypropylene tubes (Nalge Nunc, Rochester, New York, USA) until analysed. The analysis was carried out using a Perkin Elmer Sciex ELAN DRC II inductively coupled plasma-mass spectrometer (PerkinElmer Life and Analytical Sciences, Shelton, Connecticut, USA) equipped with dynamic reaction cell (DRC-ICP-MS) technology. The ICP-MS was operated according to a standard operating procedure that is certified and approved for use in New York State. 8

Briefly, 500 μl of urine was diluted 1+19 with 2% (v/v) HNO3 (Veritas double-distilled; GFS Chemicals, Powell, Ohio, USA), 0.005% Triton X-100 as a surfactant (Sigma-Aldrich, St. Louis, Missouri, USA), and 1 mg/l gold and 10 μg/l gallium, rhodium, yttrium and iridium (Spex Certiprep, Metuchen, New Jersey, USA) as internal standards. Multi-element calibration standards were prepared from a National Institute of Science and Technology (NIST)-traceable stock solution (High Purity Standards, Charleston, South Carolina, USA) and a six-point calibration curve was used for each element. Pooled human urine was used to matrix-match the calibration standards. Calibration solutions, reagents and urine samples were prepared under conditions (clean room and class IIB biosafety cabinet) certified as class 100 or better. Urine 114Cd was measured in the standard mode along with molybdenum to correct for a potential polyatomic interference from 98MoO4+ at m/z 114.

This analytical method has been validated against NIST SRM 2670a Toxic Elements in Urine, as well as secondary reference materials. The laboratory participates successfully in a number of external quality assessment schemes specifically for trace elements in urine, including those operated by (1) L’Institut National de Santé Publique du Québec, Centre de Toxicologie du Québec, Canada, (2) Friedrich-Alexander University, Erlangen, Germany and (3) the University of Surrey, Guildford, UK Trace Elements scheme. The laboratory organises the NYS Department of Health’s Proficiency Testing program for trace elements in urine. Quality control during the course of the study included analysis of four concentration levels of urine-based internal quality control (IQC) materials after calibration and every 10 specimens and at the end of every analytical run. The coefficient of variation of the mean of the first and last IQC samples per day on 9 days over the 6-month period in which these samples were assayed was 9.1% at 0.08 μg/l, 9.1% at 2.06 μg/l, 6.2% at 6.97 μg/l, and 1.6% at 10.45 μg/l. The method detection limit for cadmium in urine, calculated from data obtained over 20 independent runs, was 0.02 μg/l, while the limit of quantitation was 0.07 μg/l. The possibility of a polyatomic interference from the presence of high levels of molybdenum on low concentrations of cadmium in urine was reported recently. 9 This can result in the formation of molybdenum oxide in the argon plasma leading to a polyatomic overlap at all the major isotopes for cadmium. Therefore, we measured the molybdenum concentration in urine so that mathematical correction based on the molybdenum concentration in each urine sample could be carried out if required.

Blood lead was measured with an Hitachi 8100 Zeeman background-corrected atomic absorption spectrophotometer 10 (Hitachi Instruments, Tokyo, Japan) at the Institute of Industrial Medicine, a certified reference laboratory for lead in South Korea. Tibia lead levels were assessed via a 30 min measurement of the left mid-tibia diaphysis using 109Cd in a back-scatter geometry to fluoresce the K-shell x-rays of lead. The lead x-rays were recorded with a radiation detector and then quantified and compared to calibration data to estimate the concentration of lead in bone. 11–13

Serum and urine creatinine were measured via a Dimension clinical chemistry system using a Flex reagent cartridge in a modified kinetic Jaffe assay (model RXL; Dade Behring, Glasgow, Delaware, USA). Measured creatinine clearance, in ml/min, was defined as: ([urinary creatinine in mg/dl×urine volume in ml]/serum creatinine in mg/dl)×collection time in minutes. Glomerular filtration rate, in ml/min/1.73 m², was estimated using the abbreviated Modification of Diet in Renal Disease (MDRD) formula: 186.3×(serum creatinine)−1.154×(age) −0.203×0.742 (if the participant was female). 14, 15 Creatinine clearance was calculated with the Cockroft-Gault equation (140−age×weight in kg)/(72×serum creatinine) for males; multiplied by 0.85 for females. 16 NAG activity (expressed in μmol substrate converted per hour) was measured using the PPR. NAG test kit (P.P.R. Diagnostics, London, UK).
Statistical analysis

The goals of the analysis were to: (1) evaluate associations between urine cadmium levels and kidney outcomes (serum creatinine, eGFR, measured and calculated creatinine clearances, and NAG) in current and former lead workers, while controlling for covariates; and (2) to evaluate effect modifiers of those associations, also controlling for covariates. Statistical analysis was completed using SAS/STAT and SAS/GRAPH software, v 9.1 of the SAS System for Windows.

Initially, variable distributions were examined. Cadmium adjusted for urine creatinine (µg/g creatinine) was right skewed and thus was ln-transformed to minimise influential outliers. The NAG distribution also showed departures from normality and levels were thus ln-transformed; the adequacy of this transformation was subsequently confirmed by examination of the residuals from the final regression models. In linear regression models, associations of urine cadmium with outcomes were evaluated in two ways: the traditional approach in which cadmium concentration is adjusted for urine dilution by dividing by urine creatinine, and a more recent approach in which urine cadmium and creatinine are both included as separate covariates in the model.17 The latter approach has been recommended for study populations that include groups likely to differ by muscle mass; both men and women with a wide age range are represented in our study population. As analyses using urine cadmium corrected for molybdenum concentration were similar to those with uncorrected data, results from uncorrected data are presented.

Covariate selection utilised a priori variables (age, gender and BMI) in modelling that initially included urine cadmium with other biologically relevant variables in separate models. Variables were retained in the final model if they substantially changed either the urine cadmium regression coefficient or the explanatory value ($r^2$) of the model for any of the kidney outcomes, were statistically significant, or were relevant based on a priori knowledge or hypotheses inherent to this study (eg, blood and tibia lead and enrolee status (phase I vs II study entry)). Additional covariates that were assessed for inclusion using this approach were diabetes and hypertension (both based on participant report of physician diagnosis or medication use), regular analgesic use (based on questionnaire data on medication usage), self-reported work status (current vs former lead worker), enrolee status (phase I vs II study entry), systolic and diastolic blood pressure (average of three measurements), tobacco use (smoking status: never, former, current), smoking dose (cigarettes per day>years of smoking) in quartiles for current smokers and dichotomised for former smokers, alcohol consumption (never, former, current), education (<middle school graduate, <high school graduate, high school graduate, >high school) and annual income (=10, 10–20, 20–30, 30–40 and >40 million won). Blood and tibia lead were added to final models after all other covariates were selected. Associations between urine cadmium and kidney outcomes were also examined in three groups stratified by tertile of eGFR in order to determine whether associations were potentially consistent with reverse causality that is, present only in participants with reduced renal function. Finally, in order to examine the impact of lead-related hyperfiltration, models were examined in former workers. In a sensitivity analysis, models were assessed in 684 lead workers with the 28 primary lead smelter workers removed since a wider range of metal exposures are encountered in primary smelters. Results were consistent with the larger population (data not shown). As in previous analyses,7 models were evaluated for linear regression assumptions and the presence of outlying points using added variable plots.18 When applicable, models were repeated without outliers. Models were also assessed for collinearity through examination of variance inflation factors and conditional indices.

RESULTS

Selected demographics, exposure and health outcome measures

Information on demographics, cadmium and lead biomarkers, kidney outcomes and selected covariates from the fourth evaluation is presented in table 1 for all 712 lead workers. The population included 149 (20.9%) women and 234 (32.9%) former lead workers. Mean (SD) urine cadmium and blood and tibia lead levels, in all lead workers, were 1.15 (0.66) µg/g creatinine, 23.1 (14.1) µg/dl and 26.6 (28.9) µg Pb/g bone mineral, respectively. Mean values for the glomerular filtration measures were in the normal range.

Similar information was also compared by phase I and II study enrolment status (see supplementary online table 1). As expected, the proportion of former lead workers was higher among returning phase I study enrolees. The two groups also differed by current smoking, alcohol ingestion, education and proportion of women. Urine cadmium levels were similar; however, phase II enrolees had lower lead dose levels.

In all 712 lead workers, urine cadmium was positively correlated with tibia lead and age but negatively correlated with
blood lead ($r_t=0.08, 0.46$ and $-0.11$ respectively; $p<0.05$ for each). However, when examined by worker status, urine cadmium remained associated with age in all three groups but was only correlated with the lead biomarkers in younger, current workers; both associations were positive ($r_t=0.19, p=0.003$ and $r=0.12, p=0.06$ for blood and tibia lead, respectively; table 2).

**Associations of urine cadmium with kidney outcomes**

In all 712 lead workers, after adjustment, ln-urine cadmium was significantly ($p<0.05$) associated with three of the four glomerular filtration measures in a paradoxical pattern; higher urine cadmium was associated with lower serum creatinine, higher calculated creatinine clearance and higher eGFR (table 3). The added variable plot for the fully adjusted association between ln-urine cadmium and eGFR illustrates the direction of this association (figure 1). In contrast, urine cadmium was not associated with measured creatinine clearance. However, urine cadmium was significantly and positively associated with NAG, the sole kidney outcome in this analysis that does not reflect glomerular filtration but rather is a proximal tubular marker. Associations were consistent in models with cadmium and urine creatinine entered as separate covariates without ln-transformation (data not shown). Associations between urine cadmium and kidney measures were not substantially altered by adjustment for lead dose. These paradoxical associations were apparent early in model building. Higher ln-urine cadmium (modelled as μg/g creatinine) was associated with lower serum creatinine in unadjusted models; the β coefficient declined but remained significant in a priori models adjusted for age, sex and BMI (data not shown). Similarly, higher ln-urine cadmium was associated with higher eGFR in unadjusted models although the association was not statistically significant unless adjusted for either sex or age. In contrast, higher ln-urine cadmium was significantly associated with lower calculated creatinine clearance in unadjusted models. Adjustment for age resulted in significant associations in the paradoxical direction observed in the final models.

Ln-urine creatinine was associated with all kidney outcomes analysed but in the opposite direction compared to associations between ln-urine cadmium and each outcome (table 3). In models without adjustment for urine dilution, ln-urine cadmium was associated with all kidney outcomes except NAG (table 3). However, associations were three to fourfold higher with adjustment for ln-urine creatinine for all of the filtration measures except measured creatinine clearance. In order to

### Table 2 Spearman correlation coefficients for age and cadmium and lead biomarkers in 712 current and former lead workers

<table>
<thead>
<tr>
<th></th>
<th>Urine cadmium, μg/g</th>
<th>Blood lead, μg/dl</th>
<th>Tibia lead, μg/g</th>
<th>Bone mineral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current workers aged &lt;44.8 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>0.34***</td>
<td>0.04</td>
<td>0.13*</td>
<td></td>
</tr>
<tr>
<td>Urine cadmium</td>
<td>0.19**</td>
<td>0.12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood lead</td>
<td></td>
<td>0.45***</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current workers aged &gt;44.8 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>0.17**</td>
<td>0.17**</td>
<td>0.19**</td>
<td></td>
</tr>
<tr>
<td>Urine cadmium</td>
<td>–0.02</td>
<td>–0.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood lead</td>
<td>0.66***</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Former workers</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>0.33***</td>
<td>0.21**</td>
<td>0.40***</td>
<td></td>
</tr>
<tr>
<td>Urine cadmium</td>
<td>–0.001</td>
<td>0.07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood lead</td>
<td>0.61***</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p<0.05; **p<0.01; ***p<0.001.

### Table 3 Associations between urine cadmium, modelled with and without urine creatinine adjustment, and kidney outcomes in 712 lead workers

<table>
<thead>
<tr>
<th>Kidney outcome</th>
<th>Model 1</th>
<th></th>
<th></th>
<th></th>
<th>Model 2</th>
<th></th>
<th></th>
<th></th>
<th>Model 3</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum creatinine, mg/dl</td>
<td>β</td>
<td>(95% CI)</td>
<td>Model r²</td>
<td>β</td>
<td>(95% CI)</td>
<td>Model r²</td>
<td>β</td>
<td>(95% CI)</td>
<td>Model r²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ln-urine cadmium, μg/g creatinine</td>
<td>–0.066</td>
<td>(–0.090 to –0.042)**</td>
<td>0.34</td>
<td>–0.066</td>
<td>(–0.091 to –0.041)**</td>
<td>0.34</td>
<td>–0.018</td>
<td>(–0.032 to –0.004)*</td>
<td>0.31</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ln-urine creatinine, mg/dl</td>
<td>0.095</td>
<td>(0.038 to 0.093)**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calculated creatinine clearance, ml/min</td>
<td></td>
<td>6.3 (3.3 to 9.2)***</td>
<td>0.50</td>
<td>6.6</td>
<td>(3.6 to 9.6)***</td>
<td>0.50</td>
<td>2.8</td>
<td>(1.1 to 4.5)**</td>
<td>0.50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ln-urine cadmium, μg/g g/g creatinine</td>
<td>–5.1</td>
<td>(–8.4 to –1.8)**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ln-urine creatinine, mg/dl</td>
<td>–8.6</td>
<td>(–12.3 to –4.9)**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimated glomerular filtration rate, ml/min</td>
<td></td>
<td>8.7 (5.4 to 12.0)***</td>
<td>0.17</td>
<td>8.7</td>
<td>(5.4 to 12.1)***</td>
<td>0.17</td>
<td>2.3</td>
<td>(0.42 to 4.2)*</td>
<td>0.15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ln-urine cadmium, μg/g g/g creatinine</td>
<td>–8.6</td>
<td>(–12.3 to –4.9)**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ln-urine creatinine, mg/dl</td>
<td>11.5</td>
<td>(5.9 to 17.1)***</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measured creatinine clearance, ml/min</td>
<td></td>
<td>–3.4</td>
<td>(–8.5 to 1.7)</td>
<td>0.24</td>
<td>–1.4</td>
<td>(–6.4 to 3.6)</td>
<td>0.29</td>
<td>7.1</td>
<td>(4.3 to 10.0)***</td>
<td>0.27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ln-urine cadmium, μg/g g/g creatinine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ln-urine creatinine, mg/dl</td>
<td></td>
<td>11.5</td>
<td>(5.9 to 17.1)***</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ln-NAG, μmol/l/h g creatinine</td>
<td></td>
<td>0.27</td>
<td>(0.17 to 0.37)***</td>
<td>0.20</td>
<td>0.26</td>
<td>(0.16 to 0.36)***</td>
<td>0.20</td>
<td>0.030</td>
<td>(–0.03 to 0.09)</td>
<td>0.16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ln-urine creatinine, mg/dl</td>
<td></td>
<td>–0.31</td>
<td>(–0.42 to –0.20)**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p<0.05; **p<0.01; ***p<0.001.

† Models also adjusted for age, gender, body mass index, work status (current vs former lead worker), smoking dose (cigarettes per day X years of smoking) in quartiles for current smokers and ex-smoker status, diastolic blood pressure, alcohol consumption (never, former, current), education (middle school graduate, high school graduate, >high school), annual income (<10, 10–20, 20–30, 30–40 and >40 million won), enrollee status (phase I vs II study entry), and blood and tibia lead.

evaluate whether selection bias could have contributed to the observed associations, we adjusted for enrollee status in regression models. Although phase II enrollees had significantly lower glomerular filtration measures, associations between cadmium and those measures were unchanged.

Urine cadmium associations in eGFR subgroups
Models in the population stratified by tertile of eGFR were examined in order to determine whether associations were present only in participants with reduced kidney function and thus potentially consistent with reverse causality (lower levels in urine due to lack of cadmium excretion). After adjustment, paradoxical associations between urine cadmium and eGFR were observed in participants in the highest (≥105.0 ml/min/1.73 m²) as well as the lowest eGFR tertile (<38.9 ml/min/1.73 m²); however, no significant association was observed in the middle tertile (table 4). In contrast, associations with NAG were consistently positive in the expected direction in all three eGFR groups.

Associations in former lead workers
In order to determine whether the paradoxical cadmium associations could be due to lead-related hyperfiltration, fully adjusted models were examined in 280 former lead workers whose blood lead levels were negatively associated with eGFR, a pattern consistent with traditional lead-related nephrotoxicity (β coefficient (95% CI) = −0.38 (−0.74 to −0.05)). However, urine cadmium remained positively associated with eGFR in these workers as well (β coefficient (95% CI) = 8.7 (3.2 to 14.2)).

DISCUSSION
We compared associations of urine cadmium with four measures of glomerular filtration and NAG, a proximal tubular early biological effect marker, to determine the impact of cadmium co-exposure on kidney function in the presence of occupational lead exposure. In 712 lead workers, higher urine cadmium was associated with higher NAG. Paradoxically, higher urine cadmium was also associated with lower serum creatinine and higher eGFR and calculated creatinine clearance. In subgroup analyses stratified by tertile of eGFR, these associations were not confined to participants with eGFR in the lowest tertile. Urine cadmium was positively associated with eGFR even in former workers in whom lead-related hyperfiltration was not apparent.

Although the study population is occupationally exposed to lead, mean and median urine cadmium levels are consistent with environmental exposure in the Korean general population. Median blood cadmium was 1.55 µg/l in 1902 participants in the Korean National Health and Nutrition Examination Survey conducted in 2005.20 Our cadmium levels were measured in urine; however, in US NHANES data, median urine cadmium levels in adults, although lower, are similar to median blood cadmium (0.27 µg/g creatinine and 0.4 µg/l, respectively, in NHANES data from 2003–4).21 Questionnaire data in our study support the non-occupational nature of cadmium exposure. Only 12 participants reported occupational exposure on a questionnaire; seven used cadmium as a stabiliser in plastics and two were among the 28 participants employed in a primary lead smelter where occupational cadmium exposure is likely (median urine cadmium in those 25 employees was 1.47 µg/g creatinine).

Cadmium, at higher levels of exposure, is a well established nephrotoxicant associated with decreased glomerular filtration and chronic kidney disease.1 However, few studies have evaluated associations between low-level cadmium dose and glomerular filtration. Both blood and urine cadmium were associated with lower creatinine clearance and serum cystatin C-based eGFR after adjustment for sociodemographic factors, CKD risk factors, and blood lead in 820 Swedish women 55–64 years of age.2 In a general US population, blood cadmium was associated with lower eGFR after adjustment.4 In contrast, neither blood nor urine cadmium was associated with measured or calculated creatinine clearance in the baseline Cadmibel study, at least in models that included blood lead.22 Similarly, blood cadmium was not associated with serum creatinine in a study of 300 adults;23 neither blood nor urine cadmium was significantly associated with serum cystatin C in 200 adolescents.24 Urine cadmium was obtained in a subset of lead workers (n=191) in the first evaluation of the current longitudinal study and was significantly associated with NAG but not blood urea nitrogen.
Two studies have reported associations between urine cadmium and glomerular filtration measures in the same paradoxical direction observed herein. After adjustment, higher urine but not blood cadmium was associated with higher measured creatinine clearance in the 5-year follow-up of the Cadmibel study although the level of statistical significance was not reported. Similarly in European children, in models that adjusted for sex, lead, mercury, arsenic and significant metal cross-products, higher urine cadmium was associated with lower serum creatinine but was not significantly associated with serum $\beta_2$ microglobulin or cystatin C. Blood cadmium was not associated with any of these measures. Higher blood lead was associated with lower levels of all three, consistent with hyperfiltration.

Table 4: Associations between urine cadmium and selected kidney outcomes in models stratified by eGFR tertile (n=712)

<table>
<thead>
<tr>
<th>Kidney function measure</th>
<th>eGFR &lt;88.9 ml/min/1.73 m² (n=228)</th>
<th>eGFR 88.9-102.9 ml/min/1.73 m² (n=240)</th>
<th>eGFR ≥103.0 ml/min/1.73 m² (n=234)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ln-urine cadmium, µg/l</td>
<td>$\beta$ Coefficient (95% CI) Model $r^2$</td>
<td>$\beta$ Coefficient (95% CI) Model $r^2$</td>
<td>$\beta$ Coefficient (95% CI) Model $r^2$</td>
</tr>
<tr>
<td>Ln-urine creatinine, mg/dl</td>
<td>3.1 (0.7 to 5.4)* 0.26</td>
<td>0.92 ($-0.5$ to 2.3) 0.10</td>
<td>6.5 (1.7 to 11.3)** 0.13</td>
</tr>
<tr>
<td>Ln-NAG, µmol/h/creatinine</td>
<td>0.22 (0.06 to 0.39)** 0.32</td>
<td>0.18 ($-0.02$ to 0.38) 0.23</td>
<td>0.34 (0.17 to 0.51)** 0.28</td>
</tr>
<tr>
<td>Ln-urine creatinine, mg/dl</td>
<td>$-0.25$ ($-0.43$ to $-0.03$)**</td>
<td>$-0.26$ ($-0.47$ to $-0.05$)*</td>
<td>$-0.43$ ($-0.62$ to $-0.23$)**</td>
</tr>
</tbody>
</table>

* $p<0.05$; ** $p<0.01$; *** $p<0.001$.

Trivalent metals, however, are excreted in the urine as intact molecules, and therefore may be more efficiently removed from the body through the kidney. In this study, urinary cadmium was positively associated with lower serum creatinine and higher glomerular filtration rate, although the level of statistical significance was not reported. Similarly, in European children, in models that adjusted for sex, lead, mercury, arsenic and significant metal cross-products, higher urine cadmium was associated with lower serum creatinine but was not significantly associated with serum $\beta_2$ microglobulin or cystatin C. Blood cadmium was not associated with any of these measures. Higher blood lead was associated with lower levels of all three, consistent with hyperfiltration.

A number of hypotheses for the paradoxical associations (higher urine cadmium with lower serum creatinine and higher glomerular filtration) observed in these data must be considered. Given the similarities between lead and cadmium, it is possible that these associations represent cadmium-induced hyperfiltration. However, we are not aware of longitudinal animal or human data with cadmium exposure showing an initial increase in glomerular filtration followed by subsequent decline similar to the data of Khalil-Manesh et al. that was critical to our understanding of the lead associations we observed in these workers.

Adjustment of cadmium dose for urine dilution using urine creatinine may also be a factor. Although a large literature discusses optimal approaches to adjustment of urinary biomarkers for urine dilution, the additional complexity of assessing associations between urine markers and kidney outcomes is rarely addressed. In our data, urine cadmium was adjusted with the same urine creatinine value that was used in the measured creatinine clearance calculation. This may be a factor in the inconsistent associations with measured creatinine clearance compared to the three other filtration measures. However, urine cadmium was also significantly associated with serum creatinine, calculated creatinine clearance, eGFR and NAG in fully adjusted models. The correlation between creatinine levels from the 4 h urine collection and those from the spot urine used to adjust NAG ($r=0.49$; $p<0.0001$) is a likely explanatory factor in the association between urine creatinine and NAG. The explanation for associations between urine creatinine and the serum creatinine-based kidney outcomes is less clear since these associations were adjusted for age, sex and BMI.

In our data, urine creatinine was positively associated with serum creatinine and calculated and measured creatinine clearances but not eGFR in simple linear regression models (data not shown). After adjustment for age, sex and BMI, urine creatinine remained significantly associated only with measured creatinine clearance; the direction of the association was still positive. However, as shown in table 5, when urine cadmium was further added to the model, urine creatinine was again significant. These results raise concerns regarding associations between urine biomarkers and kidney function when urine creatinine is used in both and potentially for kidney outcomes using only serum creatinine. Few data are available to address this issue. Akesson et al reported no major impact on their results when urine cadmium was adjusted with urine creatinine instead of density. Studies in which non-creatinine-based measures of glomerular function were assessed reported higher cadmium dose associations with higher cystatin C and lower measures of glomerular function were assessed reported higher cadmium dose associations with higher cystatin C and lower cystatin C-based eGFR, but no significant associations were observed with serum cystatin C in two other studies.

It is also possible that these associations reflect reverse causality, a mechanism usually defined as an increase in blood concentration of a nephrotoxicant as a result of decreased excretion in CKD due to a cause unrelated to the nephrotoxicant. However, in our data, urine cadmium was positively associated with eGFR in the highest as well as the lowest tertile. Thus, if reverse causality is involved, urine cadmium levels reflect filtration over a wider range, which would imply that urinary cadmium, at these low environmental exposure levels, reflects kidney function as well as or perhaps even more than exposure. This seems unlikely given the widespread use of urine cadmium as an internal dose measure and associations reported in research to date such as the association with lung cancer observed prospectively in the Cadmibel study. The positive association between urine cadmium and NAG in our population also suggests toxicity rather than renal filtration. Urinary NAG is generated by proximal tubular cells, reflecting necrosis in the case of the NAG-B isoenzyme and milder forms of proximal tubular alteration for the NAG-A isoenzyme which contributes more to the total NAG used in this study. Thus, NAG, although a sensitive marker of cadmium nephrotoxicity, is not filtered at the glomerulus and so would not be expected to increase with GFR. However, as noted above, the NAG associations may be related to urine creatinine. Paradoxical cadmium associations may also represent a secondary effect of lead hyperfiltration. However, cadmium was positively associated...
with glomerular filtration measures in populations in which lead-related hyperfiltration was not observed: former lead workers in this study and in the Cadmibel general population study. Alterations in metal excretion due to protein binding may also be involved in paradoxical metal–kidney associations.38

Finally, limited ability to assess kidney function accurately in this population may also be a factor. The MDRD estimating equation underestimates GFR in the normal range, which is relevant for most occupational populations including these lead workers. Furthermore, greater bias with this equation in Chinese and Japanese compared to black and white subjects at levels <60 ml/min per 1.73 m² has been reported.39 However, a small study in a Korean population compared several eGFR estimating techniques with measured GFR using ⁹⁹ᵐTcDTPA renal clearance and found that eGFR estimated with the MDRD equation performed better than measured creatinine clearance or serum creatinine but less well than calculated creatinine clearance.40 Therefore, we have reported results with a range of kidney outcome assessment techniques in this study.

In conclusion, after adjustment, higher In-urine cadmium was associated with higher In-NAGs but, paradoxically, also with lower serum creatinine and higher eGFR and calculated creatinine clearance. These unexpected associations were present in participants in the highest as well as the lowest eGFR tertiles and remained even in former workers in whom lead-related hyperfiltration was not apparent. Potential explanations for these results include a normal physiological response in which renal filtration affects urine cadmium levels, the impact of adjustment for urine dilution with creatinine in kidney outcome models, and cadmium-related hyperfiltration. Additional research is required to determine which of these hypotheses is involved; analyses using specific gravity to adjust for urine dilution, cystatin C outcomes, and other metals to assess the potential impact of metal–protein binding would be very helpful as would analysis of prospective data. These associations have important implications for cadmium risk assessment related to kidney outcomes but may also have relevance for any toxicant research involving associations between urine biomarkers and kidney outcomes.

Funding
This research was supported by NIHES grant 2 ES007198 (Dr Weaver) and KRF-2000-00545 (Dr Lee) from the Korea Research Foundation.

Competing interests None.

Ethics approval This study was conducted with the approval of the Institutional Review Boards at the Soonchunhyang University School of Medicine and the Johns Hopkins University Bloomberg School of Public Health.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES
Associations of low-level urine cadmium with kidney function in lead workers

Virginia M Weaver, Nam-Soo Kim, Bernard G Jaar, et al.

*Occup Environ Med* 2011 68: 250-256 originally published online October 25, 2010
doi: 10.1136/oem.2010.056077

Updated information and services can be found at:
http://oem.bmj.com/content/68/4/250.full.html

These include:

**References**
This article cites 37 articles, 7 of which can be accessed free at:
http://oem.bmj.com/content/68/4/250.full.html#ref-list-1

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/